Ortho Clinical Diagnostics Holdings plc OCDX
17.63 +17.63
Day range unavailable
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 20.96 +18.9% upside
Now 17.63
- Target (low)
- 18.19
- Target (mean)
- 20.96
- Target (high)
- 24.68
Ratings (-1m) 5 1 buy · 4 hold · 0 sell
- Strong buy0
- Buy1
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 5
- 2 months ago 5
- 3 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.21 | 0.16 – 0.23 | 0.26 | -19.2% | 500.10M | -1.3% | 6 |
| Next quarter | 0.18 | 0.14 – 0.22 | 0.16 | +12.5% | 504.40M | +5.7% | 4 |
| Current year | 0.89 | 0.83 – 0.95 | 0.80 | +11.2% | 2.09B | +2.1% | 4 |
| Next year | 1.01 | 0.91 – 1.09 | 0.89 | +13.5% | 2.20B | +5.6% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 6, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Feb 17, 2022 | Evercore ISI Group | Upgrade | In-Line | Outperform |
| Dec 27, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Dec 27, 2021 | Barclays | Downgrade | Overweight | Equal-Weight |
| Dec 23, 2021 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Aug 5, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Jul 13, 2021 | Barclays | Maintained | — | Overweight |
| May 6, 2021 | Credit Suisse | Maintained | — | Outperform |
| May 6, 2021 | Morgan Stanley | Maintained | — | Overweight |
| Mar 3, 2021 | Barclays | Initiated | — | Overweight |
| Feb 22, 2021 | UBS | Initiated | — | Buy |
| Feb 22, 2021 | Morgan Stanley | Initiated | — | Overweight |
| Feb 22, 2021 | Credit Suisse | Initiated | — | Outperform |
| Feb 22, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Feb 22, 2021 | Piper Sandler | Initiated | — | Overweight |